Tech Company Financing Transactions
Magenta Therapeutics Funding Round
On 4/10/2018, Magenta Therapeutics received $52 million in Series C financing from Casdin Capital, Access Industries and Be The Match BioTherapies.
Transaction Overview
Company Name
Announced On
4/10/2018
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series C
Investors
Casdin Capital (Lead Investor) (Eli Casdin)
Proceeds Purpose
Proceeds from the financing will be used to advance Magenta's integrated portfolio of novel therapeutics, which are designed to address major unmet needs in bone marrow transplantation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Technology Sq. 5th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jason Gardner
Chief Medical Officer
John Davis
Chief Operating Officer
Jason Ryan
Vice President
Manisha Pai
VP - Bus. Development
Christina Isacson
VP - General Counsel
Zoran Zdraveski
VP - Human Resources
Kristen Stants
Browse more venture capital transactions:
Prev: 4/10/2018: Oncue venture capital transaction
Next: 4/10/2018: Armis venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs